Mark McClellan to Keynote Afternoon Session on Legal, Regulatory and Policy Issues
WASHINGTON, May 5 /PRNewswire-USNewswire/ -- Will personalized medicine revolutionize healthcare in the United States?
That's a key question that will be discussed at a national conference, Personalized Medicine: Promises and Challenges, sponsored by the American Association for the Advancement of Science (AAAS) and the Food and Drug Law Institute (FDLI), June 20, 2008, at AAAS Headquarters in Washington, D.C.
The meeting will include a high-level roundtable discussion in the morning and a seminar on legal, regulatory and policy issues on personalized medicine in the afternoon.
The personalized medicine stakeholders participating in the morning Roundtable -- including scientists, physicians, the pharmaceutical and insurance industries, government, patient groups, and others -- will discuss a case study, which will be used as a springboard to confront issues from the highly technical to the economic, ethical and regulatory that will need to be addressed as this new treatment and delivery system is incorporated into mainstream healthcare. The panel will be moderated by Susan Dentzer, Editor-in-Chief of Health Affairs.
Mark B. McClellan, M.D., Ph.D., Senior Fellow and Director at the Engelberg Center for Health Care Reform, The Brookings Institution and former FDA Commissioner and CMS Administrator, will keynote the afternoon session, which will focus on the legal and regulatory challenges faced by professionals practicing in areas affected by personalized medicine, including labeling issues, laboratory developed tests, IVD approval and reimbursement, and PGx-tailored drugs and companion diagnostics.
The following groups are participating organizations in this landmark event:
> American Society of Human Genetics
> Genetic Alliance
> Hastings Center
> International Pharmaceutical Privacy Consortium
|SOURCE Food and Drug Law Institute|
Copyright©2008 PR Newswire.
All rights reserved